Clinical Trial Search

Primary: Percentage of Participants With CR at EOI, as Determined by the Investigator on the Basis of Positron Emission Tomography and Computed Tomography (PET-CT) Scan — 33.33…

Primary: Change in HbA1c (Glycosylated Haemoglobin) — -0.88; -1.23; -1.56; -1.70 Percentage of HbA1c — p=<0.0001

Primary: Total Number of Smoke-free Days (Biochemically Verified) During Each 5-day Quit Assessment. — 2.7; 2.6 days of smoking abstinence

Primary: The Medication Treatment Step Assigned — 4.03; 4.05 score on a scale

Primary: Time to Sustained Improvement in Clinical Symptoms Based on Modified Jackson Scale for ARVI — 57.38; 67.75; 69.64 hours — p=0.3541

Primary: Percent of Subjects With no Heavy Drinking Days (PSNHDD) — 12; 4 Participants — p=.028

Primary: Change in Fugl-Meyer Assessment of Sensorimotor Function From Baseline to Day 100 — 14.8; 12.8; 39.7; 37.8 units on a scale

Primary: Fentanyl PCA mcg — 351.4; 360.7; 353.9 Micrograms

Primary: Percentage of Participants Who Achieved a Best Response of Complete Response, Partial Response, and Stable Disease (CR+PR+SD) (Clinical Benefit Rate) — 43.6; 43.6; 43.6…

Primary: Number of Participants With Non-serious Adverse Events (nSAEs) and Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability — 3; 10; 3; 16 Participants

Primary: Change From Baseline in HBsAg at Week 24 — -0.019; -0.020; -0.026; -0.048 log10 IU/mL — p=0.976

Primary: Percentage of Patients With Overall Haematological Response at Week 12. — 54.5; 50.0; 45.5; 50.0 percentage of particpants

Primary: Progression Free Survival — 16; 10.5 months

Primary: Number of Patients Who Tolerated the Maximum Dose — 5 Participants

Primary: Progression-free Survival — 158.25 days